Synlogic Investor Relations Material
Latest events
Q1 2025
7 May, 2025
Q4 2024
6 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Synlogic Inc
Access all reports
Synlogic Inc. is a biotechnology company focused on developing synthetic biotic medicines, which are engineered living organisms designed to treat metabolic and other diseases. The company’s platform uses genetically modified bacteria to deliver therapeutic effects within the human body, targeting diseases such as phenylketonuria (PKU) and other metabolic disorders. Synlogic’s approach aims to address unmet medical needs through innovative treatments that leverage the power of synthetic biology. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
SYBX
Country
🇺🇸 United States